首页> 外文OA文献 >ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): A retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials

【2h】

ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): A retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials

机译：ERBB2 mRNA作为HER2阳性（HER2 +）/激素受体阳性（HR +）转移性乳腺癌（BC）的预测因子与HER2封闭与内分泌治疗（ET）组合处理（ET）：对替代品和索尔本米拉试验的回顾性分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
N. Chic; T. Pascual; F. Brasó-Maristany; P. Villagrasa Gonzalez; L. Pare Brunet; F. Schettini; B. Conte; B. Adamo; M. Vidal; M. Muñoz; O. Martínez; B. Gonzalez-Farre; J. Cortés; A. Llombart-Cussac; V. Rodrik-Outmezguine; M.A. Izquierdo Delso; R. Schiff; C.K. Osborne; M. Rimawi; A. Prat;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Palbociclib in combination with trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A multi-center, randomized, open-label, phase II trial [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：Palbociclib与Trastuzumab和内分泌治疗（ET）与医生的选择（TPC）与PAM50腔内在亚型（Solti-1303 Patricia II）的乳腺癌（Solti-1303）的乳腺癌（Solti-1303）：A 多中心，随机，开放标签，第二阶段试验
2. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2-and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) [J] . Harbeck Nadia, Gluz Oleg, Christgen Matthias, Journal of Clinical Oncology . 2017,第26期

机译：人表皮生长因子受体2（HER2） - 阳性早期乳腺癌（BC）的脱升升级策略：对西德语研究组的最终分析辅助动态标记调整的个性化治疗试验优化BC HER2早期风险评估和治疗反应预测 - 激素受体阳性期II II型随机试验 - 疗效，安全性和预测标记为12周的Neoadjuvant Trastuzumab Omtansine，或没有内分泌治疗（ET）
3. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE [J] . Johnston Stephen R. D., Hegg Roberto, Im Seock-Ah, Journal of Clinical Oncology . 2018,第8期

机译：III期，双人表皮生长因子受体2（HER2）的随机研究与Lapatinib Plus Trastuzumab相结合，与Her2阳性激素受体阳性转移性乳腺癌的绝经后妇女中的芳香酶抑制剂组合：替代
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer [O] . Beverly Moy, Patrick Neven, Fabienne Lebrun, 2014

机译：Bosutinib与芳香酶抑制剂来曲唑的组合：绝经后妇女评估局部晚期或转移性激素受体阳性/ HER2阴性乳腺癌的一线内分泌治疗的II期试验
6. 180TiP Palbociclib, trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A randomized phase II trial [O] . E.M. Ciruelos, P. Villagrasa, M. Oliveira, 2020

机译：180tip Palbociclib，Trastuzumab和内分泌治疗（ET）与METSICIAN的选择（TPC）治疗转移性HER2-阳性和激素受体阳性（HER2 + / HR +）乳腺癌（BC）用PAM50腔内在亚型（Solti-1303 Patricia II）：随机期二期试验

ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): A retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials

著录项

引文网络

相似文献

相关主题

期刊订阅